Shi Chen1, Yunfang Wang2, Li An3, Zhong-ting Fei4, Tian Li5. 1. Department of Respiratory Medicine, Affiliated Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing University of Traditional Chinese Medicine, Nanjing 210029, PR China. 2. Department of Respiratory Medicine, Affiliated Wuxi City Hospital of Traditional Chinese Medicine, Nanjing University of Traditional Chinese Medicine, Wuxi, 214071, China. 3. Department of Gerontology, The Affiliated Zhong Da Hospital of Southeast University, 87 Dingjiaqiao, Nanjing 210009, PR China. 4. Department of Respiratory Medicine, NO4 Hospital of huai'an, Huai'an, Jiangsu, 223002, PR China. 5. Department of Respiratory Medicine, Nanjing Chest Hopital, Nanjing, Jiangsu, 210029, PR China. Electronic address: cshonest@yeah.net.
Abstract
BACKGROUND: Survivin in pleural effusion is a promising marker for the diagnosis of malignant pleural effusion. METHODS: Based on the principles and methods of Cochrane systematic reviews, PubMed, EMBASE, Web of Knowledge (ISI), the Cochrane Library, and China National Knowledge Infrastructure (CNKI) databases were searched to identify studies that assessed the diagnostic value of survivin in pleural effusion for malignant pleural effusion. Stata 12 and Meta-disc 1.4 software were used to test the heterogeneity and to perform the meta-analysis. RESULTS: Our search returned 167 articles, of which ten fulfilled the inclusion criteria. These studies included a total of 614 patients with malignant pleural effusion and 430 patients with benign pleural effusion as controls. The summary assessments revealed that the pooled sensitivity was 0.86 (95% CI: 0.82-0.88) and the pooled specificity was 0.92 (95% CI: 0.89-0.94). The positive likelihood ratio was 8.76 (95% CI: 5.41-14.20), the negative likelihood ratio was 0.16 (95% CI: 0.13-0. 20) and the diagnostic odds ratio (DOR) was 59.72 (95% CI: 39.60-90.05). The area under the curve (AUC) for the pleural effusion survivin tests was 0.9485, and the *Q index estimate for these tests was 0.8885. CONCLUSIONS: Survivin in pleural effusion has potential diagnostic value with advanced sensitivity and specificity and it can be used as adjunct tool for non-invasive diagnosis of malignant pleural effusion.
BACKGROUND: Survivin in pleural effusion is a promising marker for the diagnosis of malignant pleural effusion. METHODS: Based on the principles and methods of Cochrane systematic reviews, PubMed, EMBASE, Web of Knowledge (ISI), the Cochrane Library, and China National Knowledge Infrastructure (CNKI) databases were searched to identify studies that assessed the diagnostic value of survivin in pleural effusion for malignant pleural effusion. Stata 12 and Meta-disc 1.4 software were used to test the heterogeneity and to perform the meta-analysis. RESULTS: Our search returned 167 articles, of which ten fulfilled the inclusion criteria. These studies included a total of 614 patients with malignant pleural effusion and 430 patients with benign pleural effusion as controls. The summary assessments revealed that the pooled sensitivity was 0.86 (95% CI: 0.82-0.88) and the pooled specificity was 0.92 (95% CI: 0.89-0.94). The positive likelihood ratio was 8.76 (95% CI: 5.41-14.20), the negative likelihood ratio was 0.16 (95% CI: 0.13-0. 20) and the diagnostic odds ratio (DOR) was 59.72 (95% CI: 39.60-90.05). The area under the curve (AUC) for the pleural effusion survivin tests was 0.9485, and the *Q index estimate for these tests was 0.8885. CONCLUSIONS: Survivin in pleural effusion has potential diagnostic value with advanced sensitivity and specificity and it can be used as adjunct tool for non-invasive diagnosis of malignant pleural effusion.
Authors: Jose D Santotoribio; Luis Del Valle-Vazquez; Angela García-de la Torre; Daniel Del Castillo-Otero; Juan-Bosco Lopez-Saez; Maria J Sanchez Del Pino Journal: PLoS One Date: 2019-09-24 Impact factor: 3.240